Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone in Indolent Lymphoproliferative Disorders
NCT00052572Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixabepilone in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL) and 3 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Complete and Partial Response Rate. Started Oct 2002; status: completed.
02
Drugs
ixabepilone
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)marginal zone lymphoma (MZL)follicular lymphoma (FL)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00052572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052572.